

Hiroshi Handa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8978243/publications.pdf>

Version: 2024-02-01

86
papers

2,466
citations

567247

15
h-index

197805

49
g-index

93
all docs

93
docs citations

93
times ranked

3933
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF- κ B-IRF1-CIITA pathway. <i>Cancer Gene Therapy</i> , 2022, 29, 225-240.	4.6	10
2	Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. <i>Cancer Science</i> , 2022, 113, 2085-2096.	3.9	15
3	Efficient detection of copy number variations using exome data: Batch- and sex-based analyses. <i>Human Mutation</i> , 2021, 42, 50-65.	2.5	18
4	Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma. <i>International Journal of Hematology</i> , 2021, 113, 592-599.	1.6	1
5	IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma. <i>Clinical and Experimental Medicine</i> , 2021, 21, 323-329.	3.6	5
6	A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. <i>British Journal of Haematology</i> , 2021, 195, 217-229.	2.5	1
7	Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent <i>ETNK1</i> Mutations in Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 1513-1513.	1.4	2
8	Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy. <i>Blood</i> , 2021, 138, 2283-2283.	1.4	0
9	Two-Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2021, 138, 1352-1352.	1.4	2
10	Prognostic Impacts of Additional Cytogenetic Abnormalities Acquired at the First Relapse in Adult Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission. <i>Blood</i> , 2021, 138, 3380-3380.	1.4	0
11	Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT. <i>Blood</i> , 2021, 138, 2925-2925.	1.4	0
12	The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study. <i>Blood</i> , 2021, 138, 1009-1009.	1.4	3
13	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. <i>Blood</i> , 2021, 138, 4725-4725.	1.4	0
14	PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma. <i>Clinical and Experimental Medicine</i> , 2020, 20, 51-62.	3.6	15
15	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. <i>International Journal of Hematology</i> , 2020, 111, 65-74.	1.6	11
16	Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7121.	4.1	16
17	A multicenter, open-label, phase II study of tirabrutinib (ONO/GS4059) in patients with Waldenström's macroglobulinemia. <i>Cancer Science</i> , 2020, 111, 3327-3337.	3.9	60
18	Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2206.	3.7	18

#	ARTICLE	IF	CITATIONS
19	Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. <i>British Journal of Haematology</i> , 2020, 191, 755-763.	2.5	0
20	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2020, 18, 632-643.	3.4	12
21	Integrin $\alpha 7$ and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma. <i>Cancers</i> , 2020, 12, 363.	3.7	13
22	PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2020, 104, 526-537.	2.2	5
23	Deficiency of mannose-binding lectin is a risk of <i>Pneumocystis jirovecii</i> pneumonia in a natural history cohort of people living with HIV/AIDS in Northern Thailand. <i>PLoS ONE</i> , 2020, 15, e0242438.	2.5	6
24	Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of ^{90}Y -lritumomab Tixetan Response. <i>Kitakanto Medical Journal</i> , 2020, 70, 79-80.	0.0	0
25	Title is missing!. , 2020, 15, e0242438.		0
26	Title is missing!. , 2020, 15, e0242438.		0
27	Title is missing!. , 2020, 15, e0242438.		0
28	Title is missing!. , 2020, 15, e0242438.		0
29	Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. <i>International Journal of Hematology</i> , 2019, 110, 654-664.	1.6	12
30	The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma. <i>Cancers</i> , 2019, 11, 1738.	3.7	61
31	Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). <i>International Journal of Hematology</i> , 2019, 109, 409-417.	1.6	3
32	Activin A: a novel urinary biomarker of renal impairment in multiple myeloma. <i>Bioscience Reports</i> , 2019, 39, .	2.4	9
33	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 1703-1711.	1.8	11
34	Human telomerase reverse transcriptase expression in a CD34 α positive hematopoietic progenitor of myelodysplastic syndrome and acute myelogenous leukemia. <i>Hematological Oncology</i> , 2019, 37, 520-522.	1.7	0
35	Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF- κ B Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Acta Haematologica</i> , 2019, 141, 135-137.	1.4	0
36	Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay. <i>Hematological Oncology</i> , 2019, 37, 316-318.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Prognostic impact of trisomy 21 in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 570-577.	2.5	4
38	Looking for Niche Research. <i>Kitakanto Medical Journal</i> , 2019, 69, 159-160.	0.0	0
39	2 Cases of Refractory Idiopathic Thrombocytopenic Purpura in Pregnancy. <i>Kitakanto Medical Journal</i> , 2019, 69, 227-232.	0.0	0
40	Short-term administration of recombinant human erythropoietin decreases B cell number in human peripheral blood. <i>Transfusion and Apheresis Science</i> , 2018, 57, 208-214.	1.0	3
41	Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. <i>Blood</i> , 2018, 131, 2552-2567.	1.4	76
42	<i>PDCD1</i> and <i>CTLA4</i> polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 180, 705-714.	2.5	16
43	Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. <i>International Journal of Hematology</i> , 2018, 108, 176-183.	1.6	3
44	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. <i>International Journal of Hematology</i> , 2018, 107, 92-97.	1.6	5
45	Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. <i>International Journal of Hematology</i> , 2018, 107, 173-184.	1.6	15
46	Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. <i>Current Medical Research and Opinion</i> , 2018, 34, 531-537.	1.9	5
47	Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. <i>Hematological Oncology</i> , 2018, 36, 792-800.	1.7	1
48	Clinical impact of serum soluble SLAMF7 in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34784-34793.	1.8	27
49	Efficacy and Safety of Intermediate dose Etoposide for Mobilization of Peripheral Blood Stem Cells in Hematopoietic Tumors. <i>Kitakanto Medical Journal</i> , 2018, 68, 43-47.	0.0	0
50	Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of ⁹⁰Y-ibritumomab Tiuxetan Response. <i>Kitakanto Medical Journal</i> , 2018, 68, 151-156.	0.0	0
51	Cyanamide Induced Aplastic Anemia. <i>Kitakanto Medical Journal</i> , 2018, 68, 261-265.	0.0	0
52	Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the ¹PDK</sup>6³RPS</sup>KA</sup> signalling axis in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 534-546.	2.5	24
53	Clinical features and prognostic impact of <i>PRDM16</i> expression in adult acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 800-809.	2.8	26
54	Long non-coding ^{RNA} <i>MALAT</i>1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 449-460.	2.5	68

#	ARTICLE	IF	CITATIONS
55	Polymorphism of IL-10 receptor \hat{I}^2 affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. <i>Hematological Oncology</i> , 2017, 35, 711-718.	1.7	7
56	Successful Treatment of Immune Reconstitution Inflammatory Syndrome with Corticosteroid for Patient with Kaposi's Sarcoma Extending into the Respiratory Tract and Both Lungs. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2017, 91, 25-30.	0.0	1
57	Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2016, 96, 245-251.	2.2	7
58	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents™ era. <i>Annals of Hematology</i> , 2016, 95, 1465-1472.	1.8	11
59	Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma. <i>Oncology Letters</i> , 2016, 12, 3523-3530.	1.8	9
60	I. Epidemiology and Prognostic Change of Multiple Myeloma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 1202-1208.	0.0	2
61	Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial. <i>Blood</i> , 2016, 128, 3315-3315.	1.4	0
62	Gene polymorphisms of mannose-binding lectin confer susceptibility to <i>Pneumocystis pneumonia</i> in HIV-infected patients. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 769-775.	1.7	11
63	Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression. <i>Blood</i> , 2015, 126, 3013-3013.	1.4	2
64	Differences in Expression Patterns of DNMTs and TSG Proteins in Lymphoid Tissue Section Play an Important Role in Their Association. <i>Blood</i> , 2015, 126, 2657-2657.	1.4	0
65	The Polymorphisms Of Base Excision Repair Genes Influence The Cytogenetic Risk Factors In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1355-1355.	1.4	0
66	The Polymorphism Of Base Excision Repair Gene, XRCC1 Arg399Gln Is Associated With The Therapy-Related Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 4085-4085.	1.4	0
67	Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia. <i>Cancer Science</i> , 2012, 103, 1513-1517.	3.9	33
68	Association Between Micro-RNA and Epigenetic Modifiers DNA Methyltransferases (DNMTs), Histone Deacetylases (HDACs) in Multiple Myeloma (MM) and Monoclonal Gammopathy with Undetermined Significance (MGUS). <i>Blood</i> , 2012, 120, 3942-3942.	1.4	4
69	Flow cytometric detection of human telomerase reverse transcriptase (hTERT) expression in a subpopulation of bone marrow cells. <i>Leukemia Research</i> , 2010, 34, 177-183.	0.8	7
70	Identification of a Primary Target of Thalidomide Teratogenicity. <i>Science</i> , 2010, 327, 1345-1350.	12.6	1,614
71	Prognostic Importance of Soluble Form IL-2 Receptor α (sIL-2R α) and Its Relationship with Surface Expression of IL-2R α of Lymphoma Cell in Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy: a Retrospective Analysis of 409 Cases. <i>Blood</i> , 2009, 114, 1935-1935.	1.4	1
72	JAK2 Mutation Status in Granulocytes, Platelets and Erythrocytes Differs Between Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2008, 112, 5228-5228.	1.4	22

#	ARTICLE	IF	CITATIONS
73	Status of the Immunoglobulin Heavy Chain and Light Chain Genes in Chronic Lymphocytic Leukemia and Related Disorders. <i>Blood</i> , 2008, 112, 4161-4161.	1.4	0
74	Innate Immunity in Idiopathic Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2008, 112, 4907-4907.	1.4	0
75	Sub-acute Toxicosis Caused by a Multiple Doses Tegafur/Uracil (UFT) for Suicide: A Case Report. <i>Kitakanto Medical Journal</i> , 2007, 57, 317-320.	0.0	1
76	Acute Myeloid Leukemia Presenting as Subcutaneous and Epidural Granulocytic Sarcoma Inside and Outside of the Frontal Bone. <i>Kitakanto Medical Journal</i> , 2007, 57, 183-185.	0.0	1
77	IL-10-592 Polymorphism Predicts the Clinical Outcome of Japanese Patients with Multiple Myeloma and MGUS.. <i>Blood</i> , 2007, 110, 4759-4759.	1.4	0
78	Interleukin-10 Gene Polymorphism Reflects the Severity of Chronic Idiopathic Thrombocytopenic Purpura.. <i>Blood</i> , 2007, 110, 2111-2111.	1.4	0
79	JAK2 Mutation in Granulocytes and Platelets and X-Chromosome Gene-Based Clonal Analysis in Chronic Myeloproliferative Disorders.. <i>Blood</i> , 2006, 108, 4896-4896.	1.4	0
80	IL-10 Promoter Region -592A/C Genotype Increases the Risk of Multiple Myeloma in Japanese Patients.. <i>Blood</i> , 2006, 108, 5015-5015.	1.4	0
81	Identification of Inherited Macrothrombocytopenias Based on Mean Platelet Volume among Patients Diagnosed with Idiopathic Thrombocytopenia.. <i>Blood</i> , 2005, 106, 3981-3981.	1.4	0
82	Detection of Human Telomerase Reverse Transcriptase (hTERT) Protein Expression in Bone Marrow Cells of Hematological Disorder by Flow Cytometry.. <i>Blood</i> , 2004, 104, 4337-4337.	1.4	0
83	Comparison between CD4 and CD8 Lymphocytes as Controls for Methylation-Based Clonal Assay.. <i>Blood</i> , 2004, 104, 3847-3847.	1.4	0
84	High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2003, 71, 283-288.	2.2	146
85	Non-myeloablative Stem Cell Transplantation. <i>Kitakanto Medical Journal</i> , 2003, 53, 369-375.	0.0	0
86	Development of Bilateral Malleolus Skin Ulcers During Hydroxyurea Treatment in an Elderly Patient with Chronic Myelogenous leukemia.. <i>Kitakanto Medical Journal</i> , 1998, 48, 167-169.	0.0	0